Ng M, Gakidou E, Lo J, et al. Global, regional, and national prevalence of adult overweight and obesity, 1990–2021, with forecasts to 2050: a forecasting study for the global burden of disease study 2021. Lancet. 2025;405:813–38.
Christensen S, Nelson C. Chronicity of obesity and the importance of early treatment to reduce cardiometabolic risk and improve body composition. Obes Pillars. 2025;15:100175.
Article PubMed PubMed Central Google Scholar
Riaz H, Khan MS, Siddiqi TJ, et al. Association between obesity and cardiovascular outcomes: a systematic review and meta-analysis of mendelian randomization studies. JAMA Netw Open. 2018;1:e183788.
Article PubMed PubMed Central Google Scholar
Mao D, Lau ESH, Wu H et al. Risk associations of long-term HbA1c variability and obesity on cancer events and cancer-specific death in 15,286 patients with diabetes—a prospective cohort study. Lancet Reg Health West Pac 2022;18.
Yoong J, Schnecke V, Aekplakorn W, et al. Population-level impact of weight loss on predicted healthcare spending and the incidence of obesity-related outcomes in the Asia-Pacific region: a modelling study. BMC Glob Public Health. 2024;2:68.
Article PubMed PubMed Central Google Scholar
Fottrell E, Costello H, Ahmed N, et al. Cognitive function and associations with demographic, socioeconomic, health and behavioural factors among older adult men and women in rural Bangladesh: a population-based cross-sectional study. Lancet Reg Health-Southeast Asia. 2025;36:100575.
Article PubMed PubMed Central Google Scholar
Perdomo CM, Cohen RV, Sumithran P, et al. Contemporary medical, device, and surgical therapies for obesity in adults. Lancet Lond Engl. 2023;401:1116–30.
LeBlanc ES, Patnode CD, Webber EM, et al. Behavioral and pharmacotherapy weight loss interventions to prevent obesity-related morbidity and mortality in adults: updated evidence report and systematic review for the US preventive services task force. JAMA. 2018;320:1172–91.
Liang L, Liang L, Huang Y, et al. Incidence and risk factors of in-hospital gastrointestinal-related complications following bariatric surgery: a retrospective nationwide inpatient sample database study. Obes Surg. 2025;35:1790–9.
Kosmalski M, Deska K, Bąk B, et al. Pharmacological support for the treatment of obesity-present and future. Healthc Basel Switz. 2023;11:433.
Pasarica M, Dhurandhar NV, Stensel DJ. Obesity management with next-generation drugs. Int J Obes. 2025;49:367–8.
Huang P-F, Wang Q-Y, Chen R-B, et al. A new strategy for obesity treatment: revealing the frontiers of anti-obesity medications. Curr Mol Med. 2025;25:13–26.
Article CAS PubMed Google Scholar
Kokkorakis M, Chakhtoura M, Rhayem C, et al. Emerging pharmacotherapies for obesity: a systematic review. Pharmacol Rev. 2025;77:100002.
Wong HJ, Sim B, Teo YH, et al. Efficacy of GLP-1 receptor agonists on weight loss, BMI, and waist circumference for patients with obesity or overweight: a systematic review, meta-analysis, and meta-regression of 47 randomized controlled trials. Diabetes Care. 2025;48:292–300.
Article CAS PubMed Google Scholar
Tewari J, Qidwai KA, Tewari A, et al. Efficacy and safety of triple hormone receptor agonist retatrutide for the management of obesity: a systematic review and meta-analysis. Expert Rev Clin Pharmacol. 2025;18:51–66.
Article CAS PubMed Google Scholar
Jastreboff AM, le Roux CW, Stefanski A, et al. Tirzepatide for obesity treatment and diabetes prevention. N Engl J Med. 2025;392:958–71.
Article CAS PubMed Google Scholar
Sillassen CDB, Petersen JJ, Kamp CB, et al. Adverse effects with tirzepatide: a protocol for a systematic review with meta-analysis and trial sequential analysis. BMJ Open. 2025;15:e094947.
Article PubMed PubMed Central Google Scholar
Verma Y, Gimpaya N, Tran W, et al. A81 Gastrointestinal adverse events associated with Glucagon-Like Peptide-1 (Glp-1) agonists in overweight patients: a systematic review and meta-analysis. J Can Assoc Gastroenterol. 2025;8:i31–2.
Article PubMed Central Google Scholar
Wen X, Zhang B, Wu B, et al. Signaling pathways in obesity: mechanisms and therapeuticinterventions. Signal Transduct Target Ther. 2022;7:1–31.
Sedgwick P. Phases of clinical trials. BMJ. 2011;343:d6068–6068.
National Library of Medicine. ClinicalTrials.gov Glossary Terms n.d. https://clinicaltrials.gov/study-basics/glossary. Accessed 21 May 2025.
Zwierzyna M, Davies M, Hingorani AD, et al. Clinical trial design and dissemination: comprehensive analysis of clinicaltrials.gov and pubmed data since 2005. BMJ. 2018;361:k2130.
Article PubMed PubMed Central Google Scholar
Dodds M, Xiong Y, Mouksassi S, et al. Model-informed drug repurposing: a pharmacometric approach to novel pathogen preparedness, response and retrospection. Br J Clin Pharmacol. 2021;87:3388–97.
Bosquez-Berger T, Szanda G, Straiker A. Requiem for rimonabant: therapeutic potential for cannabinoid CB1 receptor antagonists after the fall. Drugs Drug Candidates. 2023;2:689–707.
Coutinho W, Halpern B. Pharmacotherapy for obesity: moving towards efficacy improvement. Diabetol Metab Syndr. 2024;16:6.
Article PubMed PubMed Central Google Scholar
Müller TD, Blüher M, Tschöp MH, et al. Anti-obesity drug discovery: advances and challenges. Nat Rev Drug Discov. 2022;21:201–23.
Luo J, Wu M, Chen W. Geographical distribution and trends of clinical trial recruitment sites in developing and developed countries. J Health Inf Dev Ctries. 2017;11.
Jeyakumar Y, Richardson L, Sarma S, et al. Representation of racialised and ethnically diverse populations in multicentre randomised controlled trials of GLP-1 medicines for obesity: a systematic review and meta-analysis of gaps. BMJ Glob Health. 2024;9:e017177.
Comments (0)